SITC Gynecologic Cancer Immunotherapy Guideline

SITC's Cancer Immunotherapy Guidelines program is a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure recommendations are unbiased, transparent, and balanced. 

The recommendations in this guideline provide a valuable clinical decision-making tool to help guide oncologists and other advanced practice providers with selection of appropriate immunotherapeutic regimens, diagnostics and biomarker testing, and patient quality of life considerations.

Published Guideline 

READ GUIDELINE

Updated Content (last reviewed 5/25/24)
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines, SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.

The information below provides an overview of the updates made to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer" since its publication in Journal for ImmunoTherapy of Cancer (JITC).  

Rapid Update v1.1 Summary

• The FDA granted approval of pembrolizumab with chemoradiotherapy FIGO 2014 Stage III-IVA cervical cancer on January 12, 2024. Based on this approval, the Gynecologic Cancer CPG has been updated in the following location: "Immunotherapy for the treatment of cervical cancer - Recommended immunotherapy treatments for cervical cancer" (including Table 2).
• The FDA granted approval of dostarlimab with carboplatin and paclitaxel, followed by single-agent dostarlimab for dMMR or MSI-H (as determined by an FDA-approved test) primary advanced or recurrent endometrial cancer on July 31, 2023. Based on this approval, the Gynecologic Cancer CPG has been updated in the following location: "Immunotherapy for the treatment of endometrial cancer - Recommended immunotherapy treatments for endometrial cancer" (including Table 3).

Guideline Education

SITC is pleased to offer companion education resources in support of the gynecologic cancer CPG. These activities feature faculty comprised of the guideline expert panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios. The education available features one-hour webinars, available free and on-demand, that take a deeper look at the guideline recommendations.

Practical Management Pearls for Immunotherapy for the Treatment of Gynecologic Cancer

• This one hour on-demand webinar features members of the guideline Expert Panel. These faculty members discuss how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.

Case Studies in Immunotherapy for the Treatment of Gynecologic Cancer

• This one hour on-demand webinar features members of the guideline Expert Panel. These faculty members discuss case studies that illustrate execution of SITC guideline recommendations, as well as discussion on difficult topics related to case management.